Exosome-loaded tussah silk fibroin targeting nanocapsule as well as preparation and application thereof
The preparation of tussah silk fibroin-targeted nanocapsules by transient nanoprecipitation method, combined with REDV peptide, solved the problem of lack of targeting exosome delivery, achieved the effective role of exosomes in the process of vascular endothelialization, and promoted the endothelium. Cell proliferation and migration ensure endothelialization and long-term function of small-diameter artificial blood vessels.
Patent Information
- Application Number
- CN202411181090.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing exosome delivery technology lacks targeting, which leads to a significant reduction in the role of vascular endothelialization, making it difficult to effectively promote endothelialization and long-term functional maintenance of small-diameter artificial blood vessels.
The exosome-loaded tussah silk fibroin-targeted nanocapsules were prepared by transient nanoprecipitation method. By modifying tussah silk fibroin as a wall layer, it combined with REDV peptide to provide targeting, ensuring that exosomes reach specific sites and promoting endothelial cells Proliferation and migration.
Targeted delivery of exosomes is achieved, the proliferation and migration of endothelial cells is promoted, and the endothelialization process is accelerated. The nanocapsules have good biocompatibility, high loading, safe and non-toxic, and biodegradable.
Smart Images

Figure CN119033728A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to an exosome-loaded tussah silk fibroin targeted nanocapsule and a preparation method and application thereof. Background Art
[0002] At present, the best surgical option for cardiovascular disease is autologous bypass transplantation, but the source of blood vessels is limited. Only large-caliber artificial blood vessels can be used clinically. Small-caliber artificial blood vessels (inner diameter ≤ 6mm) cannot be used clinically due to their small caliber, slow flow rate, easy to cause thrombosis, poor patency and other problems. When artificial blood vessels are implanted in the body, they will cause mechanical damage to the blood vessels, causing abnormal growth of vascular endothelial cells and smooth muscle cells in the damaged area, and the endothelialization of the inner surface of the artificial blood vessels is slow, all of which are not conducive to the maintenance of the long-term function of the artificial blood vessels, thus leading to transplantation failure. Therefore, it is crucial to promote the regeneration of the endothelial layer at the implantation site and the inner surface of the lumen of the artificial blood vessel.
[0003] Gene therapy is an effective strategy to achieve rapid endothelialization of damaged blood vessels. It can deliver genes to specific sites and then transfect them in situ, regulate the physiological activity of endothelial cells and smooth muscle cells, achieve endothelialization, and inhibit proliferation. Exosome therapy can be used as an effective gene therapy to achieve rapid endothelialization of blood vessels. This is because exosomes carry small molecules such as DNA, RNA, and lipids. If these substances can be expressed in endothelial cells, they can promote endothelial cell proliferation and migration, and then promote the endothelialization process of artificial blood vessels, so that the endothelial layer of blood vessels in the lesion site can be regenerated, thereby effectively avoiding the problems of easy blockage and restenosis of small-caliber artificial blood vessels after surgery, and further ensuring the long-term function of artificial blood vessels. At present, although exosome technology has achieved a certain degree of breakthrough, the delivery of exosomes is often not targeted, which greatly reduces its effect. Therefore, the construction of an exosome system that can be delivered in a targeted manner is of great significance for the targeted and efficient treatment of related diseases.
[0004] Chinese patent CN116286603A discloses a method for preparing engineered exosomes with targeting of atherosclerotic plaques, which collects natural exosomes released by vascular endothelial cells through laminar shear stress and combines them with targeting polymer HA-PEG-Mal using TCEP reducing agent, and obtains targeted exosomes through engineering treatment of exosomes. Chinese patent CN116077426A discloses an exosome targeted drug delivery system capable of injecting and sustained-release of small molecule compounds, which is to encapsulate BNTA in exosomes, construct a nanoscale delivery system Exo-BNTA, modify Exo-BNTA by chemical methods, graft chondrocyte affinity polypeptide CAP to it, construct a drug delivery system CAP-Exo-BNTA with chondrocyte targeting, and then encapsulate it in silk protein hydrogel, which provides targeting for exosomes by chemical methods, which may cause damage to other proteins or lipids on exosomes. Summary of the invention
[0005] In order to solve the above technical problems, the purpose of the present invention is to provide a targeted nanocapsule of tussah silk fibroin loaded with exosomes, and its preparation and application. Nanocapsules encapsulating exosomes are prepared by instantaneous nanoprecipitation method to achieve effective targeted delivery of exosomes. Tussah silk fibroin is selected as the wall layer of the nanocapsule. On the one hand, it has excellent biocompatibility, biodegradability and the RGD peptide sequence it contains can promote cell adhesion and proliferation. On the other hand, its rich groups provide active sites for modified grafted targeting peptides.
[0006] The above object of the present invention is achieved through the following technical solutions:
[0007] The first aspect of the present invention provides a method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules, comprising the following steps:
[0008] (1) dissolving tussah silk fibroin (ASF) and polyethyleneimine (PEI) in a solvent at 0-4°C, adjusting the pH to 7.8-8.0, adding a carboxyl activation reagent (EDC), and reacting to obtain a cationized tussah silk fibroin (CASF) solution;
[0009] (2) adding thiopyridinium polyethylene glycol carboxyl (OPSS-PEG-COOH) and a carboxyl activation reagent to the cationic tussah silk fibroin solution obtained in step (1) at 0-4° C. to react, adding Arg-Glu-Asp-Val (REDV) peptide solution for grafting after the reaction is completed, and obtaining cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide (CASF-REDV) after dialysis and drying;
[0010] (3) dissolving the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide obtained in step (2) in a solvent to obtain a cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide; dissolving exosomes (Exos) in a buffer solution to obtain an exosome solution; mixing the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and water to obtain the exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDVNPs).
[0011] The present invention first uses PEI and REDV peptide to modify ASF to obtain CASF-REDV solution, and uses an instantaneous nanoprecipitation method to prepare modified silk fibroin nanocapsules loaded with Exos, wherein exosomes are used as a core layer and modified silk fibroin is used as a wall layer. The REDV peptide (polypeptide targeting endothelial cells) and exosomes in the nanocapsule are combined to provide targeting for the exosomes, which can help the exosomes reach specific parts and effectively play their role; and to a greater extent promote the proliferation, migration and tube formation of endothelial cells, accelerate the endothelialization process; and at the same time have the advantages of good biocompatibility, high loading capacity, safety, non-toxicity, and biodegradability.
[0012] Furthermore, in step (1), the tussah silk fibroin protein is prepared by the following method: a. degumming tussah silk: adding sodium carbonate (Na2CO3) to deionized water at 98-100°C, stirring until completely dissolved, adding tussah cocoon shells for degumming, washing and drying to obtain tussah silk fibroin fibers; b. dissolving and dialyzing tussah silk fibroin protein: dissolving the obtained tussah silk fibroin fibers in a bath ratio of 1: (10-15) in a calcium nitrate tetrahydrate (Ca2NO3·4H2O) solution, cooling to room temperature after complete dissolution, then dialyzing and filtering to obtain a tussah silk fibroin protein solution, freeze-drying it to obtain tussah silk fibroin protein for storage.
[0013] Furthermore, in step (1), the mass ratio of the tussah silk fibroin to polyethyleneimine is 100:(4-8).
[0014] Furthermore, in step (1), the mass ratio of the tussah silk fibroin protein to the carboxyl activation reagent is (4-10):(1-2).
[0015] Furthermore, in step (1), the carboxyl activation reagent is 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide (EDC).
[0016] Furthermore, in step (1), the solvent is water, preferably deionized water.
[0017] Furthermore, in step (1), the molecular weight of the PEI is 300 to 2000 Da.
[0018] Furthermore, in step (1), 2-morpholineethanesulfonic acid (MES) is added to adjust the pH.
[0019] In a specific embodiment, in step (1), ASF is dissolved in deionized water to obtain an ASF solution, and 4 to 8% (w PEI / w ASF )PEI solution, add MES solution to adjust the solution pH to 7.8-8.0, add EDC, stir slowly, and react in an ice bath for 6-8 hours. After the reaction is completed, place it in a refrigerator at 4-5°C overnight, dialyze it in deionized water the next day, and filter it to obtain a CASF solution.
[0020] Furthermore, in step (2), the carboxyl activation reagent is 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide.
[0021] Furthermore, in step (2), the mass ratio of the mercaptopyridine polyethylene glycol carboxyl group, the carboxyl activation reagent and the cationic tussah silk fibroin protein in the cationic tussah silk fibroin protein solution is (0.25-1.5):(1.5-5):(50-150).
[0022] Preferably, in step (2), the mass ratio of the mercaptopyridine polyethylene glycol carboxyl group to the cationic tussah silk fibroin in the cationic tussah silk fibroin solution is (0.5-1):100.
[0023] Preferably, in step (2), the mass ratio of the carboxyl activation reagent to the cationized tussah silk fibroin in the cationized tussah silk fibroin solution is (1-3):100.
[0024] Furthermore, in step (2), the mass ratio of Arg-Glu-Asp-Val peptide in the Arg-Glu-Asp-Val peptide solution to cationized tussah silk fibroin in the cationized tussah silk fibroin solution is (0.1-1):(50-150), preferably (0.3-0.5):100.
[0025] In a specific embodiment, in step (2), a CASF solution is prepared, to which 0.5 to 1% (w OPSS / w CASF )OPSS-PEG-COOH and 1~3% (w EDC / w CASF )EDC, stir slowly in an ice bath for 2-3 hours, and after the reaction is complete, add 0.3-0.5% (w REDV / w CASF )REDV peptide solution, stir slowly in an ice bath for 4-5 hours, and after the reaction is completed, dialyze the solution, freeze-dry it and store it for later use.
[0026] Furthermore, in step (3), the solvent is an acetic acid (HAc) aqueous solution, and the concentration of acetic acid in the acetic acid aqueous solution is 1.99-2.01 wt %. The CASF-REDV prepared in step (2) is insoluble in common organic solvents, such as dimethyl sulfoxide (DMSO), acetonitrile (ACN) and dimethylformamide (DMF).
[0027] Furthermore, in step (3), the concentration of the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide in the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide solution is 0.5 to 2 mg / mL.
[0028] Furthermore, in step (3), the buffer is PBS buffer.
[0029] Furthermore, in step (3), the concentration of exosomes in the exosome solution is 1.5 to 2.5 μg / mL.
[0030] Furthermore, in step (3), the water is preferably deionized water.
[0031] Furthermore, in step (3), the volume ratio of the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and water is 1:(1-2):(2-3).
[0032] Furthermore, in step (3), the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and water are introduced into a mixing chamber for mixing, and the speed of introducing into the mixing chamber is 5 to 20 mL / min.
[0033] The present invention adopts an instantaneous nanoprecipitation method using a four-inlet vortex mixer to prepare Exos@CASF-REDVNPs.
[0034] In a specific embodiment, in step (3), the lyophilized CASF-REDV is dissolved in a solvent to prepare a CASF-REDV solution with a concentration of 0.5-2 mg / mL; Exos is dissolved in a 0.01-0.03 M PBS buffer to prepare an Exos solution with a concentration of 1.5-2.5 μg / mL. The CASF-REDV solution, the exosome solution and deionized water are fed into the mixing chamber at a speed of 5-20 mL / min, and Exos@CASF-REDV NPs are obtained by rapid micromixing.
[0035] The second aspect of the present invention provides exosome-loaded tussah silk fibroin targeted nanocapsules obtained by the preparation method described in the first aspect.
[0036] The Exos@CASF-REDV NPs prepared by the present invention have a particle size of 155.6-250.6 nm, a dispersion index (PDI) of 0.04-0.2, and a zeta potential of 7.08-21.9 mV.
[0037] The third aspect of the present invention provides the use of the exosome-loaded tussah silk fibroin targeted nanocapsules described in the second aspect in tissue engineering.
[0038] The Exos@CASF-REDV NPs provided by the present invention can be used to promote the growth, proliferation, and migration of various cells, and can be used to promote the repair and regeneration of various tissues, such as modifying artificial blood vessels and promoting the endothelialization process after blood vessel implantation.
[0039] Beneficial effects of the present invention:
[0040] 1. The present invention first uses PEI and REDV peptide to modify ASF to obtain CASF-REDV solution, and uses the instantaneous nanoprecipitation method to prepare modified silk protein nanocapsules loaded with Exos, wherein exosomes are used as the core layer and modified silk protein is used as the wall layer. The REDV peptide (polypeptide targeting endothelial cells) and exosomes in the nanocapsule are combined to provide targeting for the exosomes, which can help the exosomes reach specific parts and effectively play their role; and to a greater extent promote the proliferation, migration and tube formation of endothelial cells, accelerate the endothelialization process; at the same time, it has the advantages of good biocompatibility, high loading capacity, safety, non-toxicity and biodegradability.
[0041] 2. The Exos@CASF-REDV NPs prepared by the present invention have a particle size of 155.6-250.6 nm, a PDI of 0.04-0.2, and a zeta potential of 7.08-21.9 mV, and can be used to promote the growth, proliferation, and migration of various cells, and can be used to promote the repair and regeneration of various tissues, such as modifying artificial blood vessels and promoting the endothelialization process after vascular implantation. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 Transmission electron microscopy images of Exos@CASF-REDV NPs prepared in Example 1 and CASF-REDV NPs prepared in Comparative Example 1.
[0043] Figure 2 These are CLSM images of Exos@CASF-REDV NPs prepared in Example 1 after fluorescence labeling; wherein, (a) is FITC-labeled CASF-REDV, (b) is PKH26-labeled Exos, and (c) is a composite image of FITC and PKH26 labeling.
[0044] Figure 3SEM image (a), particle size and PDI diagram (b), zeta potential diagram (c) and encapsulation efficiency diagram (d) of Exos@CASF-REDV NPs prepared in Examples 1 to 7.
[0045] Figure 4 SEM images (A), particle size and PDI diagram (B), and zeta potential diagram (C) of Exos@CASF-REDV NPs prepared in Example 1, CASF-REDV NPs prepared in Comparative Example 1, and Exos@CASF NPs prepared in Comparative Example 2.
[0046] Figure 5 This is a data graph showing the biocompatibility of Exos@CASF-REDV NPs prepared in Example 1 with different addition amounts on endothelial cells determined by the CCK-8 method.
[0047] Figure 6 CLSM images of the uptake of REDV peptide by different cells (HUVECs, L929 and MSC) by Exos@CASF-REDV NPs prepared in Example 1 and Exos@CASF NPs prepared in Comparative Example 2.
[0048] Figure 7 Flow cytometric histograms of the uptake of Exos@CASF-REDV NPs prepared in Example 1 and Exos@CASF NPs prepared in Comparative Example 2 by different cells (HUVECs, L929 and MSC) by REDV peptide.
[0049] Figure 8 The scratch experiment results of the test control group, Exos@CASF-REDV NPs prepared in Example 1, CASF-REDV NPs prepared in Comparative Example 1, and Exos@CASF NPs prepared in Comparative Example 2 on HUVEC cell migration; wherein (a) is the cell migration image at 0h, 12h and 24h, and (b) is the cell migration rate data graph at 12h and 24h. DETAILED DESCRIPTION
[0050] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0051] The present invention provides a method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules, comprising the following steps:
[0052] (1) dissolving tussah silk fibroin (ASF) and polyethyleneimine (PEI) in a solvent at 0-4° C., adjusting the pH to 7.8-8.0, and adding a carboxyl activation reagent (EDC) to obtain a cationic tussah silk fibroin (CASF) solution;
[0053] (2) adding thiopyridinium polyethylene glycol carboxyl (OPSS-PEG-COOH) and a carboxyl activation reagent to the cationic tussah silk fibroin solution obtained in step (1) at 0-4° C. to react, adding Arg-Glu-Asp-Val (REDV) peptide solution for grafting after the reaction is completed, and obtaining cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide (CASF-REDV) after dialysis and drying;
[0054] (3) dissolving the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide obtained in step (2) in a solvent to obtain a cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide; dissolving exosomes (Exos) in a buffer solution to obtain an exosome solution; mixing the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and deionized water to obtain the exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs).
[0055] In a specific embodiment, the preparation method comprises the following steps:
[0056] (1) Preparation of cationic tussah silk fibroin (CASF) solution: ASF was dissolved in deionized water to prepare an ASF solution with a concentration of 10 mg / mL (w / v), and 4-8% (w / v) of PEI / w ASF )PEI solution (concentration of 10mg / mL (w / v)), stir rapidly, and after the pH of the solution stabilizes, add 0.1mol / LMES to adjust the pH of the solution to 7.8-8.0, add EDC, stir slowly, and react in an ice bath for 6h. After the reaction is completed, place it in a 4℃ refrigerator overnight, dialyze it in deionized water the next day, and filter it to obtain a CASF solution.
[0057] (2) Preparation of cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val (REDV) peptide (CASF-REDV): A 3 mg / mL (w / v) CASF solution was prepared, and 0.5-1% (w / v) of OPSS / w CASF )OPSS-PEG-COOH and 1~3% (w EDC / w CASF)EDC, stir slowly in an ice bath for 2 h. After the reaction is complete, add 0.3-0.5% (w REDV / w CASF )REDV peptide solution (0.5 mg / mL (w / v)) was slowly stirred in an ice bath for 4 h. After the reaction was completed, the solution was dialyzed and freeze-dried for later use.
[0058] (3) Preparation of exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs): The freeze-dried CASF-REDV was dissolved in HAc to prepare a CASF-REDV solution with a concentration of 0.5-2 mg / mL; Exos was dissolved in 0.01 M PBS to prepare an Exos solution with a concentration of 1.5-2.5 μg / mL, and then loaded into a 5 mL syringe. The CASF-REDV solution, Exos solution, and deionized water in two channels were delivered into the mixing chamber at a speed of 5-20 mL / min, and Exos@CASF-REDV NPs were obtained by rapid micromixing.
[0059] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0060] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.
[0061] In the following embodiments, tussah silk fibroin is prepared by the following method: a. degumming tussah silk: adding Na2CO3 to deionized water at 100°C, stirring until completely dissolved, adding tussah cocoon shells for degumming, washing and drying to obtain tussah silk fibroin fibers; b. dissolution and dialysis of tussah silk fibroin: dissolving the obtained tussah silk fibroin fibers in a bath ratio of 1:10 in a Ca2NO3·4H2O solution, and after complete dissolution, cooling to room temperature, then dialyzing, filtering, and obtaining a tussah silk fibroin solution, which is freeze-dried to obtain tussah silk fibroin for storage.
[0062] The molecular weight of PEI in the following examples is 1800 Da.
[0063] Example 1
[0064] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs), comprising the following steps:
[0065] (1) Preparation of cationic tussah silk fibroin (CASF) solution: ASF was dissolved in deionized water to prepare an ASF solution with a concentration of 10 mg / mL. 30 mL of 10 mg / mL ASF solution was added to a beaker, and then 10 mg / mL PEI solution was added and stirred rapidly. After the pH of the solution stabilized, 0.1 mol / L MES was added to adjust the pH of the solution to 7.9. 60 mg EDC was added and continued to be stirred slowly. The reaction was carried out in an ice bath for 6 hours. After the reaction was completed, it was placed in a 4°C refrigerator overnight. The next day, it was dialyzed in deionized water (3.5 kDa) for three days, and the water was changed every 2 hours. After the dialysis was completed, it was filtered using a cotton ball to obtain a CASF solution.
[0066] (2) Preparation of cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val (REDV) peptide (CASF-REDV): Add 30 mL of 3 mg / mL CASF solution to a beaker, add 0.9 mL of 1 mg / mL OPSS-PEG-COOH and 2.7 mg EDC, and stir slowly for 2 h in an ice bath in the dark. After the reaction is completed, add 0.6 mL of 0.5 mg / mL REDV peptide solution, stir slowly for 4 h in an ice bath in the dark. After the reaction is completed, put the solution into a dialysis bag and dialyze it in deionized water (3.5 kDa) for 3 days, changing the water every 2 h. After the dialysis is completed, a CASF-REDV solution is obtained, which is freeze-dried and stored for later use.
[0067] (3) Preparation of exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs): The freeze-dried CASF-REDV was dissolved in a 2wt% HAc aqueous solution to prepare a CASF-REDV solution with a concentration of 1.5mg / mL; Exos was dissolved in 0.01M PBS to prepare an Exos solution with a concentration of 2μg / mL, and then loaded into a 5mL syringe. The CASF-REDV solution, Exos solution, and two-channel deionized water were fed into a four-inlet vortex mixer at a speed of 15mL / min, and Exos@CASF-REDV NPs were obtained by rapid micromixing.
[0068] Example 2
[0069] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), a CASF-REDV solution with a concentration of 0.5 mg / mL is prepared.
[0070] Example 3
[0071] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), a CASF-REDV solution with a concentration of 1 mg / mL is prepared.
[0072] Example 4
[0073] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), a CASF-REDV solution with a concentration of 2 mg / mL is prepared.
[0074] Example 5
[0075] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), the CASF-REDV solution, the Exos solution and the deionized water in two channels are fed into a four-inlet vortex mixer at a speed of 5 mL / min.
[0076] Example 6
[0077] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), the CASF-REDV solution, the Exos solution and the deionized water in two channels are fed into a four-inlet vortex mixer at a speed of 10 mL / min.
[0078] Example 7
[0079] A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules (Exos@CASF-REDV NPs) is basically the same as that in Example 1, except that in step (3), the CASF-REDV solution, the Exos solution and the deionized water in two channels are fed into a four-inlet vortex mixer at a speed of 20 mL / min.
[0080] Comparative Example 1
[0081] A method for preparing tussah silk fibroin targeted nanoparticles (CASF-REDV NPs) comprises the following steps:
[0082] (1) Preparation of cationic tussah silk fibroin (CASF) solution: ASF was dissolved in deionized water to prepare an ASF solution with a concentration of 10 mg / mL. 30 mL of 10 mg / mL ASF solution was added to a beaker, and then 10 mg / mL PEI solution was added and stirred rapidly. After the pH of the solution stabilized, 0.1 mol / L MES was added to adjust the pH of the solution to 7.9. 60 mg EDC was added and continued to be stirred slowly. The reaction was carried out in an ice bath for 6 hours. After the reaction was completed, it was placed in a 4°C refrigerator overnight. The next day, it was dialyzed in deionized water (3.5 kDa) for three days, and the water was changed every 2 hours. After the dialysis was completed, it was filtered using a cotton ball to obtain a CASF solution.
[0083] (2) Preparation of cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val (REDV) peptide (CASF-REDV): Add 30 mL of 3 mg / mL CASF solution to a beaker, add 0.9 mL of 1 mg / mL OPSS-PEG-COOH and 2.7 mg EDC, and stir slowly for 2 h in an ice bath in the dark. After the reaction is completed, add 0.6 mL of 0.5 mg / mL REDV peptide solution, stir slowly for 4 h in an ice bath in the dark. After the reaction is completed, put the solution into a dialysis bag and dialyze it in deionized water (3.5 kDa) for 3 days, changing the water every 2 h. After the dialysis is completed, a CASF-REDV solution is obtained, which is freeze-dried and stored for later use.
[0084] (3) Preparation of tussah silk fibroin targeted nanoparticles (CASF-REDV NPs): The freeze-dried CASF-REDV was dissolved in a 2 wt % HAc aqueous solution to prepare a CASF-REDV solution with a concentration of 1.5 mg / mL; the CASF-REDV solution and three-channel deionized water were fed into a four-inlet vortex mixer at a rate of 15 mL / min, and CASF-REDV NPs were obtained by rapid micromixing.
[0085] Comparative Example 2
[0086] A method for preparing exosome-loaded tussah silk fibroin nanocapsules (Exos@CASF NPs) comprises the following steps:
[0087] (1) Preparation of cationic tussah silk fibroin (CASF) solution: ASF was dissolved in deionized water to prepare an ASF solution with a concentration of 10 mg / mL. 30 mL of 10 mg / mL ASF solution was added to a beaker, and then 10 mg / mL PEI solution was added and stirred rapidly. After the pH of the solution stabilized, 0.1 mol / L MES was added to adjust the pH of the solution to 7.9. 60 mg EDC was added and continued to be stirred slowly. The reaction was carried out in an ice bath for 6 hours. After the reaction was completed, it was placed in a 4°C refrigerator overnight. The next day, it was dialyzed in deionized water (3.5 kDa) for three days, and the water was changed every 2 hours. After the dialysis was completed, it was filtered using a cotton ball to obtain a CASF solution.
[0088] (2) Preparation of exosome-loaded tussah silk fibroin nanocapsules (Exos@CASF NPs): Exos were dissolved in 0.01 M PBS to prepare an Exos solution with a concentration of 2 μg / mL, which was then loaded into a 5 mL syringe. A CASF solution with a concentration of 1.5 mg / mL, an Exos solution, and two channels of deionized water were fed into a four-inlet vortex mixer at a speed of 15 mL / min, and Exos@CASF NPs were obtained by rapid micromixing.
[0089] The Exos@CASF-REDV NPs prepared in Examples 1 to 7, the CASF-REDV NPs prepared in Comparative Example 1, and the Exos@CASF NPs prepared in Comparative Example 2 were tested and subjected to biological analysis. The test results are as follows: Figures 1 to 8 shown.
[0090] Figure 1 The transmission electron micrographs of Exos@CASF-REDV NPs prepared in Example 1 and CASF-REDV NPs prepared in Comparative Example 1 are shown in FIG. Figure 1 Its microscopic morphology and structural information can be seen in the figure. The exosomes themselves are cup-shaped. The middle part of the tussah silk fibroin targeted nanocapsule encapsulating exosomes is the cup-shaped morphology of the exosomes, while the tussah silk fibroin targeted nanoparticles that do not encapsulate exosomes are solid spheres.
[0091] Figure 2 This is a confocal laser scanning microscopy (CLSM) image of the Exos@CASF-REDV NPs prepared in Example 1 after fluorescence labeling. Fluorescent isothiocyanate (FITC) was used to label cationic tussah silk fibroin, and PKH26 was used to label exosomes. Figure 2 It can be seen that the cationic tussah silk fibroin exhibits strong green fluorescence (FITC), while the red dot fluorescence (PKH26) is distributed inside the silk fibroin nanocapsules, confirming that the exosomes have been successfully encapsulated inside the modified tussah silk fibroin.
[0092] Figure 3 Scanning electron microscope (SEM) images (a), particle size and PDI (b), zeta potential (c), and encapsulation efficiency (d) of Exos@CASF-REDV NPs prepared in Examples 1 to 7. CASF-REDV / m Exos ) obtained nanocapsules with different parameters, the overall morphology of which was spherical, the particle size was 155.6-250.6nm, the PDI was 0.04-0.2, the zeta potential was 7.08-21.9mV, and the encapsulation efficiency was 49.76%-63.19%. Compared with Examples 2-7, Example 1 has a suitable particle size (227.3nm) and potential (8.94mV), good dispersibility (PDI is 0.08), and the encapsulation efficiency can reach 63.19%, which is suitable for cell endocytosis and can load exosomes to a greater extent, promoting the function of exosomes.
[0093] Figure 4 The SEM images (A), particle size and PDI diagram (B) and zeta potential diagram (C) of Exos@CASF-REDV NPs prepared in Example 1, CASF-REDVNPs prepared in Comparative Example 1 and Exos@CASF NPs prepared in Comparative Example 2 are shown. The SEM images show that the different capsules / particles prepared are all spherical. From the particle size analyzer test results, the particle size of CASF-REDV NPs prepared in Comparative Example 1 is 186.5nm, which is smaller than 227.3nm in Example 1. This may be due to the fact that the size of the exosomes themselves is 50 to 150nm, and the encapsulation of the exosomes will increase the particle size of the capsules. The particle size of Exos@CASF NPs prepared in Comparative Example 2 is 174.03nm, which is smaller than that of Comparative Example 1. This may indicate that the effect of the grafted polypeptide on the particle size of the capsule is greater than that of the encapsulated exosomes. The Zeta potential results showed that all three capsules / particles were positively charged (Example 1: 8.94 mV, Comparative Example 1: 32.77 mV and Comparative Example 2: 14.07 mV). Since the exosomes and REDV peptides themselves are negatively charged, the charge of the capsules / particles themselves will be neutralized after grafting the polypeptide or encapsulating the exosomes, causing the potential to drop. Nanocapsules with a certain positive charge help the negatively charged endothelial cells to take them up without causing cytotoxicity.
[0094] Figure 5 The data of the biocompatibility of Exos@CASF-REDV NPs prepared in Example 1 on endothelial cells was measured by CCK-8 method. The capsules were diluted with DMEM complete medium to change the amount of capsules added. Figure 5It can be seen that when the exosome concentration is above 50 ng / mL, it can significantly promote the proliferation of human umbilical vein endothelial cells. As the amount of capsule added decreases, the proliferation effect weakens and gradually becomes the same as the control group (Control, no Exos@CASF-REDV NPs added). This shows that Exo@CASF-REDV NPs have good cell compatibility and can achieve the effect of promoting endothelial cell proliferation when the exosome concentration is 50 ng / mL.
[0095] Figure 6 The CLSM images (qualitative analysis) of the Exos@CASF-REDV NPs prepared in Example 1 and the Exos@CASF NPs prepared in Comparative Example 2 for the uptake of REDV peptide by different cells (HUVECs, L929 and MSC). In order to explore whether the nanocapsules can be taken up by cells and the targeting effect of REDV peptide on the cell uptake process, FITC-labeled nanocapsules were co-incubated with HUVECs, L929 and MSC, respectively. After 6 hours, the images were recorded under a laser confocal microscope to study the targeted uptake effect of REDV peptide on the nanocapsules. Figure 6 As shown in the figure, FITC green fluorescence is used to label Exos@CASF-REDV NPs and Exos@CASF NPs, DAPI blue fluorescence is used to label the cell nucleus, and TRITC red fluorescence is used to label the cytoskeleton. Figure 6 It can be seen that the nanocapsules all appear inside the cells, surrounding the cell nucleus, indicating that the nanocapsules can be taken up by the cells into the cytoplasm, and then further absorbed and utilized by the cells. At the same time, in L929 and MSC cells, the green fluorescence of Exos@CASF-REDV NPs and Exos@CASFNPs is basically the same, while in HUVEC cells, the green fluorescence of Exos@CASF-REDV NPs in Example 1 is more than that of Exos@CASF NPs in Comparative Example 2, indicating that the presence of REDV peptide can target endothelial cells to induce more capsules to enter the cells to play a role. This is because the REDV peptide can specifically bind to the α1β4 integrin on the surface of endothelial cells, thereby inducing more capsules to enter endothelial cells.
[0096] Figure 7 Figure 2 is a flow cytometric histogram (quantitative analysis) of the uptake of Exos@CASF-REDV NPs prepared in Example 1 and Exos@CASF NPs prepared in Comparative Example 2 by different cells (HUVECs (a), L929 (b) and MSC (c)). Figure 7As shown in (a), the percentage of positive cells and the average intracellular fluorescence intensity of Exos@CASF-REDV NPs are much higher than those of Exos@CASF NPs, with significant differences, while there are no significant differences in the percentage of positive cells and the average intracellular fluorescence intensity of Exos@CASF-REDV NPs and Exos@CASF NPs in (b) and (c), which is the same as the CLSM result. This is because the REDV peptide can specifically bind to the α1β4 integrin on the surface of endothelial cells, increasing the ability of endothelial cells to take up capsules, but the effect of this peptide is not significant in improving the ability of fibroblasts and mesenchymal stem cells to take up capsules. This also confirms that the REDV peptide can provide targeting for the delivery of exosomes into endothelial cells and exert the function of exosomes to a greater extent.
[0097] Figure 8 The scratch test results of the control group (Control, no nanocapsules / particles added), Exos@CASF-REDV NPs prepared in Example 1, CASF-REDV NPs prepared in Comparative Example 1, and Exos@CASF NPs prepared in Comparative Example 2 on HUVEC cell migration were shown. HUVEC cell migration was recorded using an inverted microscope, and the migration area was analyzed using Image J to calculate the migration rate. Figure 8 As shown. At 12h, there was no significant difference between different samples and the control group. After 24h of culture, Exos@CASF-REDV NPs significantly promoted cell migration, with a migration rate of 63.10%, much higher than that of the control group (51.90%), and there was no significant difference between CASF-REDV NPs and the control group, indicating that the presence of exosomes can significantly promote the migration of HUVECs. In addition, compared with the control group 2 (53.46%), the grafting of REDV peptide significantly promoted cell migration, which also confirmed that REDV targeted endothelial cells and increased the cell uptake of capsules, thereby promoting the function of exosomes.
[0098] In summary, the Exos@CASF-REDV NPs prepared in Example 1 have a spherical morphology, a particle size of 227.3 nm, a PDI of 0.08, good dispersibility, a zeta potential of +8.94 mV, which meets the conditions for cell endocytosis, and an encapsulation efficiency of exosomes of 63.19%. The nanocapsules prepared in Example 1 not only have good biocompatibility, but also effectively increase the uptake rate of endothelial cells (from 11.2% to 42.4%), and promote the function of exosomes. Compared with the CASF-REDV NPs prepared in Comparative Example 1 and the Exos@CASF NPs prepared in Comparative Example 2, the Exos@CASF-REDV NPs prepared in Example 1 further promote the proliferation and migration of endothelial cells, thereby achieving the purpose of accelerating the endothelialization process.
[0099] Obviously, the above embodiments of the present invention are only examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. Those skilled in the art should understand that other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for preparing exosome-loaded tussah silk fibroin targeted nanocapsules, characterized in that: The following steps are involved: (1) dissolving tussah silk fibroin and polyethyleneimine in a solvent at 0-4° C., adjusting the pH to 7.8-8.0, adding a carboxyl activation reagent, and reacting to obtain a cationic tussah silk fibroin solution; (2) adding mercaptopyridine polyethylene glycol carboxyl and carboxyl activation reagent to the cationic tussah silk fibroin solution obtained in step (1) at 0-4° C. to react, adding Arg-Glu-Asp-Val peptide solution for grafting after the reaction, and obtaining cationic tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide after dialysis and drying; (3) dissolving the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide obtained in step (2) in a solvent to obtain a cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide solution; dissolving exosomes in a buffer solution to obtain an exosome solution; mixing the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide solution, the exosome solution and water to obtain the exosome-loaded tussah silk fibroin targeted nanocapsules.
2. The preparation method according to claim 1, characterized in that: In step (1), the mass ratio of the tussah silk fibroin to polyethyleneimine is 100:(4-8).
3. The preparation method according to claim 1, characterized in that: In steps (1) and (2), the carboxyl activation reagent is 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide.
4. The preparation method according to claim 1, characterized in that: In step (2), the mass ratio of the mercaptopyridine polyethylene glycol carboxyl group, the carboxyl activation reagent and the cationic tussah silk fibroin in the cationic tussah silk fibroin solution is (0.25-1.5):(1.5-5):(50-150).
5. The preparation method according to claim 1, characterized in that: In step (2), the mass ratio of the Arg-Glu-Asp-Val peptide in the Arg-Glu-Asp-Val peptide solution to the cationized tussah silk fibroin in the cationized tussah silk fibroin solution is (0.1-1):(50-150).
6. The preparation method according to claim 1, characterized in that: In step (3), the concentration of the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide in the cationized tussah silk fibroin grafted with Arg-Glu-Asp-Val peptide solution is 0.5-2 mg / mL, and the concentration of the exosomes in the exosome solution is 1.5-2.5 μg / mL.
7. The preparation method according to claim 6, characterized in that: In step (3), the volume ratio of the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and water is 1:(1-2):(2-3).
8. The preparation method according to claim 1, characterized in that: In step (3), the cationized tussah silk fibroin solution grafted with Arg-Glu-Asp-Val peptide, the exosome solution and water are introduced into a mixing chamber for mixing at a speed of 5 to 20 mL / min.
9. Tussah silk fibroin targeted nanocapsules loaded with exosomes obtained by the preparation method according to any one of claims 1 to 8.
10. Use of the exosome-loaded tussah silk fibroin targeted nanocapsules according to claim 9 in tissue engineering.
Citation Information
Patent Citations
Preparation method and application of tussah silk fibroin nanoparticles
CN110279674A
Cationization antheraea pernyi silk fibroin / adenovirus compound, and preparation method and application thereof
CN111575317A
Preparation process of stem cell exosome-loaded fibroin nanofiber hydrogel
CN113144293A
Nanoencapsulation method of cord blood mesenchymal stem cell source exosome
CN117503731A
Regenerative and restorative vascular stent covering membrane and preparation method therefor
WO2022028397A1
Cited By
Purification method of mesenchymal stem cell exosome, prepared mesenchymal stem cell exosome particles and application of mesenchymal stem cell exosome particles
CN121022735A
A method for purifying mesenchymal stem cell exosomes, and mesenchymal stem cell exosome particles prepared therefrom and uses thereof
CN121022735B
